This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
Nature Communications Open Access 13 February 2023
-
The role of the proteasome in AML
Blood Cancer Journal Open Access 02 December 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301–2307.
Guzman ML, Swiderski CF, Howard DS, Grimes BA, Rossi RA, Szilvassy SJ et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci USA 2002; 99: 16220–16225.
Riccioni R, Senese M, Diverio D, Riti V, Buffolino S, Mariani G et al. M4 and M5 acute myeloid leukaemias display a high sensitivity to Bortezomib-mediated apoptosis. Br J Haematol 2007; 139: 194–205.
Minderman H, Zhou Y, O'Loughlin KL, Baer MR . Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemother Pharmacol 2007; 60: 245–255.
Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371–3376.
Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kurdik FJ, Allred T et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058–3065.
Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG et al. Phase I study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060–1066.
Gojo I, Jiemjit A, Trepel JB, Sparreboom A, Figg WD, Rollins S et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood 2007; 109: 2781–2790.
Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rotzer S et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008; 80: 133–142.
Emanuele S, Lauricella M, Carlisi D, Vassallo B, D’Anneo A, Di Fazio P et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007; 12: 1327–1338.
Holkova B, Perkins EB, Sokol L, Richards KL, Parekh S, Elstrom R et al. A Phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large b-cell lymphoma. Blood 2011; 118, ASH abstract 779.
Weber DM, Graef T, Hussein M, Sobecks RM, Schiller GJ, Lupinacci L et al. Phase I trial of vorinostat combined with bortezomib for the treatment of relapsing and/or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk 2012; 12: 319–324.
Friday BB, Anderson SK, Buckner J, Yu C, Giannini C, Geoffroy F et al. Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer group study. Neuro Oncol 2012; 14: 215–221.
Dimopoulos MA, Jagannath S, Yoon S, Siegel D, Lonial S . Vantage 088: vorinostat in combination with bortezomib in patients with refractory/relapsed multiple myeloma: results of a global, randomized phase 3 trial. Blood 2011; 118, ASH abstract 811.
Siegel D, Dimonopoulos, Yoon S, Laubach J, Kaufman J . Vantage 095: vorinostat in combination with bortezomib in salvage multiple myeloma patients: final study results of a global phase 2b trial. Blood 2011; 118, ASH abstract 480.
Acknowledgements
Funding support for the entire clinical trial was provided jointly by Millenium and Merck.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Warlick, E., Cao, Q. & Miller, J. Bortezomib and vorinostat in refractory acute myelogenous leukemia and high-risk myelodysplastic syndromes: produces stable disease but at the cost of high toxicity. Leukemia 27, 1789–1791 (2013). https://doi.org/10.1038/leu.2013.61
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.61
This article is cited by
-
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia
Nature Communications (2023)
-
The role of the proteasome in AML
Blood Cancer Journal (2016)
-
Bortezomib/vorinostat
Reactions Weekly (2015)